ArticleJACC. Case reports2025
Accelerated Atherosclerosis in Early-Stage Breast Cancer Following Chemotherapy.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo present guidelines exist regarding the inclusion of atherogenic cancer or chemotherapy into atherosclerotic cardiovascular disease (ASCVD) screening or imaging screening guidelines. Individual physician preference often determines screening, and this is typically symptom guided. CASE SUMMARY: A 30-year-old woman with early-stage breast cancer received atherogenic chemotherapy, with no prior atherogenic risk factors. She presented with angina and dyspnea on exertion 3 years after her last round of chemotherapy. An ischemic work-up was performed, and the patient was found to have premature critical stenosis in her proximal left anterior descending artery. DISCUSSION: Because more patients are living with cancer and survivors of atherogenic chemotherapy emerge, it is becoming more critical to improve ASCVD screening modalities. TAKE-HOME MESSAGE: Expert consensus for patients with early-stage cancer treated with atherogenic chemotherapy should derive either their unique ASCVD algorithm, be included into pre-existing algorithms, or have their own multimodal imaging pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.